Table 3.

S100A8/A9 concentrations and clinical characteristics in NPSLE and non-NPSLE patients applying three NPSLE attribution models

	SLICC A model			SLICC B model			ACR model
	NPSLE	Non-NPSLE	p value	NPSLE	Non-NPSLE	p value	NPSLE	Non-NPSLE	p value
Serum S100A8/A9, ng/ml, median (range)	1560 (280–3520)	1090 (50–3540)	0.050	1460 (260–3520)	1090 (50–3540)	0.084	1400 (140–3540)	920 (50–3500)	0.011
CSF S100A8/A9, pg/ml, median (range)	316 (< 35–854)	351 (< 35–2045)	0.83	316 (< 35–1703)	351 (< 35–2045)	1.0	319 (< 35–1703)	416 (< 35–2045)	0.43
Age at study, median (range), years	41 (24–48)	36 (18–52)	0.23	39 (23–48)	37 (18–52)	0.90	40 (18–50)	35 (19–52)	0.28
Disease duration, median (range), years	10.5 (1–24)	9.5 (0–32)	0.18	10 (1–29)	10 (0–32)	0.90	10 (0–32)	10 (0–25)	0.43
SLICC/ACR-DI, median (range)	1 (0–5)	0 (0–4)	0.008	1 (0–5)	0 (0–4)	0.003	0 (0–5)	0 (0–3)	0.18
SLEDAI-2 K, median (range)	2 (0–12)	2 (0–18)	0.63	2 (0–12)	2 (0–18)	0.70	2 (0–18)	2 (0–12)	0.65

SLICC: Systemic Lupus Erythematosus International Collaborating Clinics. ACR: American College of Rheumatology. CSF: cerebrospinal fluid. DI: Damage Index. SLEDAI-2 K: SLE Disease Activity Index 2000